Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Pipeline Review, H1 2016

  • ID: 3746942
  • Report
  • Region: Global
  • 35 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • LEO Pharma A/S
  • MORE
Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Pipeline Review, H1 2016

Summary

‘Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Pipeline Review, H1 2016’, provides in depth analysis on Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) targeted pipeline therapeutics.

The report provides comprehensive information on the Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1)
- The report reviews Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • LEO Pharma A/S
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) Overview

Therapeutics Development

Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Products under Development by Stage of Development

Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Products under Development by Therapy Area

Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Products under Development by Indication

Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Pipeline Products Glance

Early Stage Products

Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Products under Development by Companies

Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Companies Involved in Therapeutics Development

Albany Molecular Research, Inc.

AstraZeneca Plc

Boehringer Ingelheim GmbH

LEO Pharma A/S

Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Drug Profiles

ALB-127158(a) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZ-13483342 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-3857 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-186908 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize MCHR1 for Weight Loss - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Dormant Projects

Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Discontinued Products

Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Featured News & Press Releases

Oct 03, 2011: AMRI Presents Final Phase I Clinical Studies Results Of Obesity Compound At 29th Annual Scientific Meeting Of Obesity Society

May 31, 2011: AMRI Announces Successful Completion Of Phase I Clinical Study Of Obesity Compound

May 19, 2011: AMRI To Present Phase I Clinical Results Of Obesity Compound At European Congress On Obesity

Jul 21, 2010: AMRI Initiates Phase I Study Of ALB-127158(a) For Treatment Of Obesity

Jun 02, 2009: AMRI Advances New Obesity Drug MCH-1 Receptor Antagonist Toward IND Submission

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Albany Molecular Research, Inc., H1 2016

Pipeline by AstraZeneca Plc, H1 2016

Pipeline by Boehringer Ingelheim GmbH, H1 2016

Pipeline by LEO Pharma A/S, H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • LEO Pharma A/S
  • MORE
Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) Melanin-concentrating hormone receptor 1 also known as MCH1 is one of the human melanin-concentrating hormone receptors. MCH1 is a target for the orexigenic peptide leptin, which supports a role for MCH receptors in the control of food intake and energy expenditure. MCH1 helps in regulation of stress, anxiety and depression.

Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.The molecules developed by Companies in Phase I and Preclinical stages are 1 and 4 respectively.

Our latest report Melanin-Concentrating Hormone Receptor 1 – Pipeline Review, H1 2016, outlays comprehensive information on the Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Albany Molecular Research, Inc.
AstraZeneca Plc
Boehringer Ingelheim GmbH
LEO Pharma A/S
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll